Voyager Acquisition Corp
VRXAW
NASDAQ Global Market0.11
USD
-0.01
- -
ISIN
CH1478199107
Return %
Stock
S&P500
1Y
-41.42
19.99
3Y
-41.42
69.40
5Y
-41.42
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christoph Antz
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Talacker 35 Zürich ZH Switzerland 8001
- IPO Date
- Jun 10, 2026
- Website
- veraxa.com
- Similar Companies
- Business
- Voyager Acquisition Corp, a Cayman Islands-domiciled special purpose acquisition company (SPAC), operates as a blank-check vehicle pursuing a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more target companies. The company focuses on identifying and combining with a high-growth business in the technology, healthcare, or life sciences sectors, with a strategic emphasis on mid- to late-stage opportunities that can benefit from public-market access and governance improvements. Voyager emphasizes a disciplined approach to evaluating potential targets, structuring complex transactions, and providing a clear path to Nasdaq listing for the combined entity. Primary business activity - Provides a listed vehicle for a planned merger or business combination with a private company - Engages in initial business opportunity screening, due diligence, and negotiation services - Arranges financing, equity and debt structuring, and post-transaction governance and compliance support - Facilitates regulatory filings, investor relations, and shareholder communications for the combined entity Founding and headquarters - Founded in 2022 - Headquarters located in Paris, Île-de-France, France, with active regulatory and investor relations engagement in multiple jurisdictions Recent developments and strategic updates - Pursues a formal business combination with VERAXA Biotech AG, targeting a Nasdaq-listed vehicle upon closing of the merger; the transaction is structured to transform Voyager into a public company under the VRXA ticker after the business combination closes - Advances through regulatory and shareholder approval processes for the planned acquisition, with anticipated closing in late 2025 to 2026 subject to customary closing conditions and listings approvals - Enhances strategic positioning through the VERAXA partnership to leverage VERAXA’s biotech platform, pipeline, and development capabilities, aligning Voyager’s public market exposure with a high-growth life sciences target - Maintains a focus on governance, financial discipline, and value creation for public investors through the post-merger entity, including robust reporting and compliance frameworks Industry and market positioning - Industry: Special purpose acquisition company; potential transformation into a publicly traded biotech-focused enterprise - Business segments: SPAC operations, merger execution services, and post-transaction governance and investor relations - Target markets: Public market investors and institutional buyers seeking exposure to biotechnology and biotech-enabled therapeutics - Geographic footprint: Represents a cross-border listing vehicle with connections to European and North American capital markets, and regulatory oversight aligned with Nasdaq listing requirements Subsidiaries and corporate structure - Voyager operates as the parent SPAC vehicle; upon completion of the Business Combination, VERAXA Biotech AG and Voyager combine into a single publicly traded company under the VRXA ticker - Post-merger governance and corporate structure anticipated to reflect a consolidated management team, with VERAXA’s biotech platform integrated into the public company’s operations Key competitive differentiators - Public-market access for a private biotech-focused company, enabling accelerated capital formation - Structured transaction processes with clear regulatory and investor communications plans - Strategic alliance with VERAXA to align scientific leadership with translational and commercial development Notes - The information reflects publicly disclosed plans and regulatory filings related to Voyager’s proposed business combination with VERAXA Biotech AG and the anticipated post-merger Nasdaq listing under VRXA.